Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

NCT ID: NCT05205330

Last Updated: 2025-10-29

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 107 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-11-23
• Study Completion Date: 2027-06-30

Brief Summary

This Phase Ib/IIa study comprises a Main Study and a Study Extension.

The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients. The fixed-dose Expansion phase will be conducted at the recommended dose for expansion (RDE), with the purpose of generating additional and more robust safety and efficacy data. 27 patients are predicted in the Dose Escalation phase and 52 in the Expansion phase, respectively.

The Study Extension explores in other metastatic GI cancers the Vorbipiprant (CR6086) RDE obtained in the Main Study. 27 patients are predicted.

No control arm was included, as the target patient population of this study consists of patients in whom the overall survival is less than 6 months and treatment options are very limited and often poorly tolerated, making unlikely that the study results can be significantly biased.

Detailed Description

In this study, the combination of the PGE2 inhibition (through the EP4 receptor antagonist CR6086) with the immune checkpoint blockade (through the anti-PD-1 AGEN2034) is being evaluated in refractory pMMR-MSS mCRC and other metastatic GI cancers. CR6086 (Vorbipiprant) is a potent and selective, orally bioavailable, targeted immunomodulator small molecule acting as an EP4 receptor antagonist. AGEN2034 (balstilimab) is a novel, fully human monoclonal immunoglobulin G4 antibody, designed to block programmed cell death 1 (PD-1) from interacting with its ligands (PD-L) PD-L1 and PD-L2, currently being developed for the treatment of advanced malignancies. EP4 receptor antagonists turn the status of the tumor microenvironment into a favourable one, i.e. immune-responsive, representing thus a rational therapeutic approach in combination with ICIs in primarily refractory cancers.

Conditions

Refractory Metastatic Colorectal Cancer; Solid Tumor; Metastatic Microsatellite-stable Colorectal Cancer; Mismatch Repair Protein Proficient; Metastatic GI Cancers; Gastric Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

30 mg (Dose Level 1)

14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 30 mg twice a day for 14 days

Group Type: EXPERIMENTAL

CR6086

Intervention Type: DRUG

oral CR6086, twice a day for 14 days

AGEN2034

Intervention Type: BIOLOGICAL

AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle

90 mg (Dose Level 2)

14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 90 mg twice a day for 14 days

Group Type: EXPERIMENTAL

CR6086

Intervention Type: DRUG

oral CR6086, twice a day for 14 days

AGEN2034

Intervention Type: BIOLOGICAL

AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle

180 mg (Dose Level 3)

14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 180 mg twice a day for 14 days

Group Type: EXPERIMENTAL

CR6086

Intervention Type: DRUG

oral CR6086, twice a day for 14 days

AGEN2034

Intervention Type: BIOLOGICAL

AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle

other mGI cancers

14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 90 mg twice a day for 14 days

Group Type: EXPERIMENTAL

CR6086

Intervention Type: DRUG

oral CR6086, twice a day for 14 days

AGEN2034

Intervention Type: BIOLOGICAL

AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle

Expansion in MSS/pMMR mCRC patients

14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 90 mg twice a day for 14 days

Group Type: EXPERIMENTAL

CR6086

Intervention Type: DRUG

oral CR6086, twice a day for 14 days

AGEN2034

Intervention Type: BIOLOGICAL

AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle

Interventions

CR6086

oral CR6086, twice a day for 14 days

Intervention Type: DRUG

AGEN2034

AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle

Intervention Type: BIOLOGICAL

Other Intervention Names

vorbipiprant; balstilimab

Eligibility Criteria

Inclusion Criteria

Main Study - patients with MSS mCRC These criteria are applicable for both Dose Escalation and Expansion part of the Main Study; criteria specific for each study part are identified with ESC=Escalation or EXP=Expansion.

1. Signed and dated informed consent obtained before undergoing any study-specific procedure

2. Male or female aged ≥18 years

3. ESC - Histologically confirmed diagnosis of adenocarcinoma originating from the colon or rectum, with known RAS and BRAF mutational status as assessed per standard practice.

EXP - Histologically confirmed diagnosis of adenocarcinoma originating from the colon or rectum, with known RAS and BRAF mutational status as assessed per standard practice.

For patients included in the Expansion part only: PD-L1 CPS or adequate tissue to perform PD-L1 CPS assessment should be available.

4. Stage IV (according to the American Joint Committee on Cancer definition)

5. Presence of measurable disease per RECIST v1.1 (based on imaging within 28 days from first study drug administration). Patients must have at least one "target lesion" to be used to assess response, as defined by RECIST v1.1 Note: Subjects with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately

6. ESC - Disease progression after at least two standard treatment lines for mCRC, including fluoropyrimidines, oxaliplatin and irinotecan and, if RAS and BRAF wild-type, cetuximab or panitumumab or, intolerance or refusal of chemotherapy regimens for mCRC Note: Previous oxaliplatin-based adjuvant treatment is considered as a treatment line if disease relapse occurred within 6 months from its completion

EXP - Disease progression after at least two standard treatment lines for mCRC, including fluoropyrimidines, oxaliplatin and irinotecan and:

1. if RAS and BRAF wild type, cetuximab or panitumumab

2. if BRAFV600E mutated encorafenib and cetuximab or intolerance or refusal of chemotherapy regimens for mCRC. Note: Previous oxaliplatin-based adjuvant treatment is considered as a treatment line if disease relapse occurred within 6 months from its completion 7. Naïve to any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints inhibitors) and EP4 receptor antagonists 8. ESC - Availability of adequate and sufficient baseline tumour tissue sample (archival or newly obtained biopsy) Note: an adequate and sufficient sample is defined as formalin fixed paraffin embedded tumour tissue sample, preferably from the most recent biopsy of a tumour lesion, collected either at the time of or after the diagnosis of metastatic disease has been made AND from a site not previously irradiated. If no tumour tissue is available, a fresh tissue from needle or excisional biopsy or from resection is required EXP - Availability of adequate and sufficient newly obtained fresh tumour tissue sample collected after ICF during the screening period and before the treatment starts. In case the biopsy collection is not feasible, according to Investigator judgement or patient decision, archival biopsy or surgical sample can be accepted after discussion with the Sponsor.

Note: an adequate and sufficient sample is defined as formalin fixed paraffin embedded tumour tissue sample, collected from a site not previously irradiated. If the formalin fixed paraffin embedded tumor tissue sample obtained after the last treatment line and 90 days before the ICF signature, the patient is considered eligible, If the fresh tissue from needle or excisional biopsy/resection is not feasible according to the Investigator judgement, the patients may be eligible after discussion with the Sponsor.

9. pMMR/MSS defined as CRC with all 4 MMR proteins intact and/or with instability at ≤1/5 locus (or 30% of loci if larger panel of markers are assayed) 10. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 11. Anticipated life expectancy ≥ 3 months 12. Adequate hematologic and end organ function, defined by the following laboratory results, obtained within 7 days before first dose of study drug treatment:

1. Hemoglobin ≥ 10 g/dL, platelet count ≥100,000/mm3, ANC ≥1500/mm3

2. Creatinine clearance ≥ 50 mL/min

3. Amylase and lipase ≤ 1.5 × ULN

4. Serum bilirubin ≤ 1.5× ULN

5. AST, ALT, and ALP ≤ 2.5 × ULN with the following exceptions:

• Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN

6. INR and PTT ≤ 1.5 × ULN.

• Patients who are on therapeutic doses of anti-coagulants should be on a stable dose for 28 days, with stable INR and PTT values.

7. Serum albumin ≥ 3.0 g/dL

13. Ability e and willingness to participate and comply with the requirements of the entire study

Study Extension - other metastatic GI cancers Cohorts A and B - Gastric cancer

1. Signed and dated informed consent obtained before undergoing any study-specific procedure

2. Male or female aged ≥18 years

3. Body weight > 40kg

4. Histologically proven advanced-stage unresectable adenocarcinoma of the stomach or the GEJ

5. Stage IV (according to the American Joint Committee on Cancer definition)

6. Available CPS or available tissue to perform CPS assessment: Cohort A: CPS≥5 - Cohort B CPS<5

7. Failure to at least one prior line of chemotherapy for metastatic disease, given with or without trastuzumab, with or without anti-PD-1. In alternative, early disease recurrence after surgery with neo-adjuvant and/or adjuvant chemotherapy (within 6 months of the last administration of chemotherapy) or progression during neo-adjuvant and/or adjuvant chemotherapy (containing fluoropyrimidine and a platinum derivative).

8. Presence of measurable disease per RECIST v1.1 (based on imaging within 28 days from first study drug administration). Patients must have at least one "target lesion" to be used to assess response, as defined by RECIST v1.1 Note: Subjects with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately

9. Naïve to EP4 receptor antagonists

10. Availability of adequate and sufficient baseline tumour tissue sample (archival or newly obtained biopsy) Note: an adequate and sufficient sample is defined as formalin fixed paraffin embedded tumour tissue sample, preferably from the most recent biopsy of a tumour lesion, collected either at the time of or after the diagnosis of metastatic disease has been made AND from a site not previously irradiated. If no tumour tissue is available, a fresh tissue from needle or excisional biopsy or from resection is required

11. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1

12. Anticipated life expectancy ≥ 3 months

13. Adequate hematologic and end organ function, defined by the following laboratory results, obtained within 7 days before first dose of study drug treatment:

<!-- -->

1. Hemoglobin ≥ 10 g/dL, platelet count ≥100,000/mm3, ANC ≥1500/mm3

2. Creatinine clearance ≥ 50 mL/min

3. Amylase and lipase ≤ 1.5 × ULN

4. Serum bilirubin ≤ 1.5× ULN

5. AST, ALT, and ALP ≤ 2.5 × ULN with the following exceptions:

• Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN

6. INR and PTT ≤ 1.5 × ULN.

• Patients who are on therapeutic doses of anti-coagulants should be on a stable dose for 28 days, with stable INR and PTT values.

7. Serum albumin ≥ 3.0 g/dL

14. Ability e and willingness to participate and comply with the requirements of the entire study

Cohort C - GI cancers other than CRC and GC

1. Signed and dated informed consent obtained before undergoing any study-specific procedure

2. Male or female aged ≥18 years

3. Body weight > 40kg

4. Histologically proven advanced-stage unresectable GI cancer other than CRC and GC

5. Stage IV (according to the American Joint Committee on Cancer definition)

6. Failure to at least one prior line of chemotherapy for metastatic disease, given with or without trastuzumab, with or without anti-PD-1. In alternative, early disease recurrence after surgery with neo-adjuvant and/or adjuvant chemotherapy (within 6 months of the last administration of chemotherapy) or progression during neo-adjuvant and/or adjuvant chemotherapy (containing fluoropyrimidine and a platinum derivative).

7. Presence of measurable disease per RECIST v1.1 (based on imaging within 28 days from first study drug administration). Patients must have at least one "target lesion" to be used to assess response, as defined by RECIST v1.1 Note: Subjects with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately

8. Naïve to EP4 receptor antagonists

9. Availability of adequate and sufficient baseline tumour tissue sample (archival or newly obtained biopsy) Note: an adequate and sufficient sample is defined as formalin fixed paraffin embedded tumour tissue sample, preferably from the most recent biopsy of a tumour lesion, collected either at the time of or after the diagnosis of metastatic disease has been made AND from a site not previously irradiated. If no tumour tissue is available, a fresh tissue from needle or excisional biopsy or from resection is required

10. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1

11. Anticipated life expectancy ≥ 3 months

12. Adequate hematologic and end organ function, defined by the following laboratory results, obtained within 7 days before first dose of study drug treatment:

<!-- -->

1. Hemoglobin ≥ 10 g/dL, platelet count ≥100,000/mm3, ANC ≥1500/mm3

2. Creatinine clearance ≥ 50 mL/min

3. Amylase and lipase ≤ 1.5 × ULN

4. Serum bilirubin ≤ 1.5× ULN

5. AST, ALT, and ALP ≤ 2.5 × ULN with the following exceptions:

• Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN

6. INR and PTT ≤ 1.5 × ULN.

• Patients who are on therapeutic doses of anti-coagulants should be on a stable dose for 28 days, with stable INR and PTT values.

7. Serum albumin ≥ 3.0 g/dL

13. Ability e and willingness to participate and comply with the requirements of the entire study

Exclusion Criteria

Criteria 38-40 are applicable to patients to be enrolled in Study Extension only.

Medical Condition/History:

Cancer and anti-cancer therapy:

1. Additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin that has undergone potentially curative therapy with no evidence of recurrence for 5 years since initiation of that curative therapy, or carcinoma in situ (breast carcinoma, cervical cancer)

2. Active brain tumour, metastasis or leptomeningeal metastases. Patients with brain metastases are eligible if these have been treated and there is no magnetic resonance imaging (MRI except where contraindicated in which CT scan is acceptable) evidence of progression for at least 8 weeks after treatment is complete and within 28 days prior to first dose of study drug administration. Cases should be discussed with the Sponsor. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (>10mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration

3. Major surgery within 28 days before Cycle 1 Day 1 or anticipation of needing such procedure during the trial

4. Treatment with any systemic or localized anti-cancer therapy, including chemotherapy, biological therapy, radiotherapy, or hormonal therapy within 28 days before initiation of Cycle 1 Day 1 or expected to require such a treatment during the trial

5. Persistent toxicity related to prior therapy, Grade >1 according to NCI CTCAE Version 5.0 Note 1: Patients must have recovered from all AEs due to previous therapies, to CTCAE ≤Grade 1 or to baseline condition. Participants with CTCAE ≤Grade 2 neuropathy or alopecia may be eligible Note 2: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment Note 3: Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease

6. Uncontrolled tumour-related pain. Patients requiring narcotic pain medication must be on a stable regimen at study entry

7. Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage more than once every 28 days. Indwelling drainage catheters are allowed

Cardiovascular:

8. Unstable angina

9. Myocardial infarction within 6 months before enrolment

10. History of stroke, reversible ischemic neurological defect, or transient ischemic attack within 6 months before enrolment

11. Uncontrolled ventricular arrhythmia

12. Congestive heart failure (New York Hearth Association class ≥II)

13. Poorly controlled hypertension

Infections:

14. Confirmed infection with SARS-CoV-2 as documented by molecular testing at nasopharyngeal swab (only if required by the epidemiological situation)

15. HIV infection

16. Active tuberculosis

17. Acute or chronic viral hepatitis B or C infection

18. Any severe infection within 14 days before Cycle 1 Day 1

General Medical History:

19. Active autoimmune disease in the past 2 years

20. History of allogenic tissue/solid organ transplant (including allogeneic bone marrow transplantation)

21. History of immunodeficiency

22. History or presence of interstitial lung disease or history of pneumonitis that has required oral or iv corticosteroids.

23. History of gastric/duodenal ulcers, colitis and/or gastrointestinal bleeding

24. History of severe gastrointestinal adverse reactions

25. History of hypersensitivity reactions to fully human monoclonal antibodies, Grade ≥ 3 according to NCI CTCAE Version 5.0

26. History of anaphylaxis, or uncontrolled asthma

27. Allergy/hypersensitivity/intolerance to any component of CR6086 or AGEN2034

28. Any other clinically relevant disease and condition, including psychiatric or substance abuse disorders, that, in the opinion of the Investigator, may jeopardize efficacy or safety assessments, confound the result of the trial or may compromise the patient's safety during trial participation

Concomitant Treatments

29. Administration of a live, attenuated vaccine within 28 days before Cycle 1 D1

30. Systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before screening Note: Corticosteroid use for management of immune-related adverse events, and/or as a premedication for iv contrast allergies/reactions is allowed.

Daily corticosteroid replacement therapy is allowed: permitted therapy are daily prednisone at doses of 5 to 7.5 mg or equivalent hydrocortisone dose, and steroid therapy administered by topical, intraocular, intranasal, and/or inhalation routes

31. Regular use of any illicit drugs or recent history (within the last year) of substance abuse (including alcohol)

Others:

32. Participation in a study with an investigational drug or medical device within 28 days before Cycle 1 Day 1 Note: Participants who have entered the follow-up phase of another investigational study may participate as long as at least 4 weeks have elapsed since the last dose of the investigational agent

33. Inability to swallow medications

34. Malabsorption conditions

35. For women of childbearing potential:

• Pregnancy (i.e. positive pregnancy test at Screening) or breastfeeding
• Failure to agree to practice a highly effective method of contraception , from enrolment up to at least 120 days after the last IMP intake
• expecting to conceive within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of study treatment

36. For sexually active men with a female partner of childbearing potential: failure to agree to use condom and refrain from donating sperm from enrolment up to at least 120 days after the last IMP intake.

37. Patients who are legally incapacitated or has limited legal capacity

Criteria for Study Extension only

38. Presence of portal hypertension

39. Presence of oesophageal varices

40. Presence of gastric infiltration, severe gastritis, duodenal or gastric ulcer, or any other condition that may lead to bleeding or perforation, as assessed by an EGDS performed during screening period.

Criteria referring to Cycle 1 D1, should be reassessed on study D1, before starting the study treatment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Agenus Inc.

INDUSTRY

Sponsor Role: collaborator

Rottapharm Biotech

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Coordinating Investigator

Role: PRINCIPAL_INVESTIGATOR

IRCCS Istituto Nazionale dei Tumori

Locations

Istituto Nazionale dei Tumori

Milan, Milano, Italy

Istituto Oncologico Veneto IRCCS

Padua, Padova, Italy

Azienda Ospedaliero Universitaria Pisana

Pisa, Pisa, Italy

Countries

Italy

Other Identifiers

2024-515446-16-00

Identifier Type: CTIS

Identifier Source: secondary_id

2020-002435-29

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CR6086-1-04

Identifier Type: -

Identifier Source: org_study_id